RE: Intellectual Property question9 May 2021 09:59
Tommy - a blinkered cult-infested gambler forum is a wrong place to ask about complex legal issues.
There is currently a patent pending (approved?), however, personally, I am not 100% sure how far it can reach.
E.g.
Case 1: The French rip off the SNG juice formula and start making and selling it much cheaper than SNG. This looks like an outright patent violation, but even in a "clear-cut" case like this, does SNG have the funds to take on the French/EU Government? If the EU benefits greatly from it, the whole thing might become political very quickly.
Also, imagine SNG's publicity if they are taking another company to court to stop them saving lives, because by saving lives they are taking a few quid off the SNG's P&L bottom line.
Case 2: France (or Argentina) develop their own formula that works almost as well and start making and selling it at a fraction of SNG's pie-in-the-sky £3k per treatment. SNG can only produce 50k treatments a month, all of them going to the UK and US, so the French are not cutting into SNG sales. Can SNG claim damages when they are not actually suffering any direct financial loss from it (i.e. SNG's sales of 50k treatments a month are still 50k and only limited by the manufacturing capacity.
Afaik, if there's no loss, there's no case but wtfdik.
Also, publicity again. SNG can't produce enough juice and don't want anyone else producing more to save lives.
Case 3: I wouldn't be surprised if more than half of the world's population is in countries that don't care much for SNG's IP and will be making knock-off Chinairgen copies anyway. Then the UK governement will buy Chinairgen instead because it's cheaper - just like they did with covid tests.
Anyone telling you SNG IP is completely, 100% risk-free is a brainwashed idiot.
PS All of the above assumes that
- SNG actually works - read the last RNS and make your own conclusions.
- SNG can actually manufacture thousands of treatments per month. This has not been the case up until now and there is no update from the company on this.